The results highlighted a previously unrecognized mechanism involving miR-29b-3p and WISP1 in response to IR, and suggested a novel treatment option for prostate cancer patients, especially for those with higher levels of the WISP1 expression. Here, CCN4 is linked to prostate cancer.